Cancer Supportive Care Drugs Market Size - By Drug Class (G-CSFs, ESAs, Anti-emetics, Bisphosphonates, Opioids, NSAIDs), Cancer type (Breast, Lung, Prostate, Colorectal, Melanoma), Distribution Channel (Hospital, Drug Store), Global Forecast (2023 – 2032)

Cancer Supportive Care Drugs Market Size - By Drug Class (G-CSFs, ESAs, Anti-emetics, Bisphosphonates, Opioids, NSAIDs), Cancer type (Breast, Lung, Prostate, Colorectal, Melanoma), Distribution Channel (Hospital, Drug Store), Global Forecast (2023 – 2032)

Cancer Supportive Care Drugs Market Size

Cancer Supportive Care Drugs Market size was estimated to be USD 14.4 billion in 2022 and is predicted to increase at a growth rate of 1.9% till 2032. Progress in cancer treatments like chemotherapy, radiation therapy, targeted therapy, and immunotherapy has elevated treatment effectiveness. Prioritizing the well-being of cancer patients has gained significant prominence in cancer care.
 

The rise in awareness and education, the aging demographic, the growing inclination towards personalized medicine, and the growing population of cancer survivors have collectively emphasized the management of long-term treatment-related effects.
 

Moreover, the increasing global incidence and prevalence of cancer contribute to a growing patient population that requires supportive care. According to American Cancer Society, Inc. over 1.9 million new cancer cases is expected to be diagnosed in the U.S. in 2023. As more individuals are diagnosed with cancer, the demand for effective supportive care drugs to manage treatment-related side effects also rises.
 

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the healthcare industry, including the cancer supportive care drugs market. Throughout the pandemic, various healthcare systems faced challenges with cancer treatment due to financial reallocation, lockdowns, and concerns about virus transmission.
 

Furthermore, numerous clinical studies for cancer medications, including supportive care drugs, were halted or postponed during the pandemic to prioritize patient safety. This interruption had implications for the development and testing of new supportive care drugs.
 

Nonetheless, telemedicine and remote healthcare services gained prominence during the pandemic to ensure patient safety. While certain supportive care services could be delivered online, the absence of in-person care might have influenced the overall management of treatment-related symptoms.
 

Cancer Supportive Care Drugs Market Trends

Some key trends in the industry include a growing focus on personalized medicine in supportive care, the development of targeted therapies for specific side effects of cancer treatment, the integration of digital health technologies, including mobile apps and telemedicine platforms, into supportive care programs. Additionally, there is a growing emphasis on managing long-term treatment-related effects, an increasing use of combination therapies that include supportive care drugs alongside cancer treatments, and the development of biologic agents, such as monoclonal antibodies, to target specific pathways involved in treatment-related symptoms. These trends reflect efforts to enhance the overall quality of life for cancer patients by efficiently managing treatment-related symptoms and providing the most effective and comprehensive supportive care.
 

Cancer Supportive Care Drugs Market Analysis

Based on drug class, the cancer supportive care drugs market is segmented into G-CSFs (granulocyte-colony stimulating factors), ESAs (erythropoiesis stimulating agents), anti-emetics, bisphosphonates, opioids, NSAIDs, and other drug types. In 2022, the G-CSFs (granulocyte-colony stimulating factors) segment accounted for the largest share of 22.8% in the industry. The main purpose for using G-CSF is to avoid neutropenia. Chemotherapy commonly impacts rapidly dividing cells, such as neutrophils in bone marrow, resulting in decreased neutrophil numbers. G-CSFs stimulate the bone marrow to produce more neutrophils, lowering the risk of severe neutropenia and related infections. In addition, due to the increased risk of infection, neutropenia could result in chemotherapy dosage reductions, delays, or suspensions. Healthcare practitioners can follow the prescribed chemotherapy treatment to attain optimal treatment results by using G-CSFs to avoid neutropenia.
 

Based on cancer type, the cancer supportive care drugs market is segmented into breast cancer, lung cancer, melanoma, prostate cancer, colorectal cancer, liver cancer, stomach cancer, and other cancer types. The breast cancer segment held the significant industry share of around 14.1% in 2022. Breast cancer treatment often involves a combination of surgery, radiation therapy, chemotherapy, and targeted therapy. Each of these modalities can cause different side effects, such as pain, nausea, fatigue, and emotional distress. Supportive care drugs address these diverse symptoms to improve patients' overall well-being. According to National Breast Cancer Foundation, Inc. in the U.S., 1 out of 8 women will be diagnosed with breast cancer over her lifetime. An estimated 297,790 women and 2,800 men will be diagnosed with invasive breast cancer in 2023.
 

Based on distribution channel, the cancer supportive care drugs market is segmented as hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a dominant industry share of 58.9% in 2022 and is expected to grow at a CAGR of 2% by 2032. Hospital pharmacists have specialized knowledge in oncology and supportive care drugs. They collaborate with healthcare teams to ensure appropriate drug selection, dosing, and administration based on individual patient needs.
 

Asia Pacific cancer supportive care drugs market accounted for significant revenue in 2022 and is expected to reach USD 6.1 billion in 2032 with a CAGR of 2.3% from 2023-2032. The Asia Pacific region has witnessed a rising incidence of cancer, attributed to factors such as population growth, aging, changing lifestyles, and environmental factors. As cancer cases increase, so does the demand for supportive care drugs to manage treatment-related symptoms.
 

Moreover, many countries in the Asia Pacific are adopting Western-style cancer treatments, including chemotherapy and targeted therapies. These therapies often come with side effects that require effective supportive care interventions.
 

Cancer Supportive Care Drugs Market Share

Major industry players operating in the cancer supportive care drugs market include

• Amgen, Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Heron Therapeutics, Inc.
• Novartis AG
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Helsinn Healthcare SA,
• Teva Pharmaceuticals Industries Ltd.,
• Fagron Group.
   

Cancer Supportive Care Drugs Market Industry News

• In June 2020, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved NYVEPRIA (pegfilgrastim-apgf), a biosimilar of Neulasta (pegfilgrastim). NYVEPRIA was developed to reduce the risk of infection, as shown by febrile neutropenia, in patients with non-myeloid malignancies taking myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
   

The cancer supportive care drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By drug class

• G-CSFs (Granulocyte-colony Stimulating Factors)
• ESAs (Erythropoiesis Stimulating Agents)
• Anti-emetics
• Bisphosphonates
• Opioids
• NSAIDs
• Other drugs

By cancer type

• Breast cancer
• Lung cancer
• Melanoma
• Prostate cancer
• Colorectal cancer
• Liver cancer
• Stomach cancer
• Other cancer types

By distribution channel

• Hospital pharmacies
• Drug stores and retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa